Maia Biotechnology, Inc. Announces $6.2 Million Financing To Advance Targeted Immuno-Oncology Studies
Oct 14, 2021•over 3 years ago
Amount Raised
$6.2 Million
Description
MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs (“MAIA”), announced today that it has raised an additional $6.2 million in an equity offering at $8/share. The proceeds of the financing will advance the company’s programs and will support the initiation of a Phase 2 clinical trial (THIO-101) evaluating the administration of THIO followed by cemiplimab in patients with advanced Non-Small Cell Lung Cancer (NSCLC). The THIO-101 trial is expected to begin this year.
FundzWatch™ Score
74
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood